Companies › Shanghai Mabgeek Biotech.Co.Ltd
2 active drug programs in 5 registered trials: 2 Phase 3, 2 Phase 2, 1 Phase 1; Respiratory, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MG-K10 Humanized Monoclonal Antibody Injection Humanized monoclonal antibody | – | Phase 3 | Prurigo Nodularis; Asthma; Seasonal Allergic Rhinitis; Atopic Dermatitis | Nov 2026 |
| MG-ZG122 Humanized Monoclonal Antibody Injection Humanized monoclonal antibody | – | Phase 2 | Bronchial Asthma | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06765005 | MG-K10 Humanized Monoclonal Antibody Injection | Phase 1 | Atopic Dermatitis | Immunology | May 2025 |
| NCT06846385 | MG-K10 Humanized Monoclonal Antibody Injection | Phase 2 | Seasonal Allergic Rhinitis | Immunology | May 2025 |
| NCT06779136 | MG-K10 Humanized Monoclonal Antibody Injection | Phase 3 | Prurigo Nodularis | Immunology | Nov 2026 |
| NCT07054034 | MG-ZG122 Humanized Monoclonal Antibody Injection | Phase 2 | Bronchial Asthma | Respiratory | May 2027 |
| NCT06837922 | MG-K10 Humanized Monoclonal Antibody Injection | Phase 3 | Asthma | Respiratory | Nov 2027 |
No annotated target.
–
Aqualung Therapeutics Connect Biopharm PPD Development, LP Upstream Bio Celldex Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.